ReviewInflammopharmacology2025
Integrating natural products with modern medicine in the treatment of gouty arthritis: a review.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Fondaparinux attenuates methotrexate-induced hepatotoxicity by regulating coagulation, endothelial dysfunction, and inflammatory signaling via the TLR4/NLRP3 and NF-κB/IL-1β/MCP-1 pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Luteolin in osteoarticular diseases: a review of preclinical studies and translational perspectives.Inflammopharmacology · 2026Review
- Modulation of AMPK/SIRT1 signaling by piribedil attenuates cyclophosphamide-induced nephrotoxicity via PI3K/Akt, MAPKs, and TLR4/NLRP3 pathways with regulation of KIM-1/NGAL.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Neutrophil extracellular traps in gout: from immune defense to pathological dynamic equilibrium.Frontiers in immunology · 2026Review
- Gout management: Patent analytics and computational drug design explores URAT1 inhibitors landscape.PloS one · 2025Article
- Comprehensive Treatment of Gout with Traditional Chinese Medicine: A Modern Pathophysiological Perspective.International journal of general medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout is an inflammatory form of arthritis caused by hyperuricemia, a condition in which uric acid levels in the body become excessively high. When this occurs, monosodium urate (MSU) crystals can accumulate in the joints, triggering intense pain, swelling, and inflammation. If left untreated, gout can lead to joint damage and other complications. Diet is a key factor in the development and management of gout since some meals may increase uric acid levels while others can help relieve symptoms. To reduce circulating urate levels, commonly used drugs include allopurinol and febuxostat. However, the intake of these medications is associated with undesirable side effects. As a result, the development of a novel active, safe anti-hyperuricaemic and anti-inflammatory medicine could be extremely beneficial in gout treatment. Natural products have become a source of new medications because of their high efficacy and low side effects, which are based on the presence of complex bioactive components. A rising number of researchers document that traditional medications can reduce serum urate levels. This article is intended to trace which herbal remedies could alleviate hyperuricemia, as well as their mechanism of actions.
Indexed as
Identifiers
40418438What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.